CASI Pharmaceuticals Announces Preliminary Results of CID-103 Clinical Trial
CASI Pharmaceuticals announced data presented from its Phase 1 open-label study of CID-103 in adult patients with immune thrombocytopenia at the 67th American Society of Hematology Annual Meeting and Exposition on December 7, 2025, in Orlando, Florida. This open-label Phase 1 dose escalation study assigned patients to sequential dose-escalating cohorts of intravenous infusions of CID-103 at 30 mg, 150 mg, 300 mg, 600 mg, and 900 mg, with a priming dose of CID-103 of either 30 mg or 150 mg administered prior to the cohort dose. Primary objective is to evaluate safety and tolerability of multiple escalating doses of CID-103. Primary efficacy endpoint is the proportion of patients achieving a platelet response, defined as a platelet count greater than or equal to 50 x 109/L and greater than or equal to 20 x 109/L above baseline on at least 2 consecutive measurements at least 7 days apart within the first twelve weeks of treatment. Other endpoints were evaluated including pharmacokinetic and pharmacodynamic markers. As of cut-off date of November 28, eleven patients have been enrolled and dosed. Interim Results: CID-103 demonstrated a manageable safety profile with only two Grade 3 treatment-related events and no dose limiting toxicities observed; All infusion-related reactions occurred with priming dose and are due to low grade AEs; Primary Efficacy Endpoint achieved in 8 of 11 patients; 6 of 8 patients achieved Complete Response with platelet improvement observed as early as one week post dose; Reduction of PD markers is consistent with the presumed CID-103 MOA resulting in the observed platelet response. "We are pleased with the safety and tolerability of CID-103 and encouraged by the 73% of patients achieving the primary efficacy endpoint," said Alex Zukiwski, CMO. "Importantly, this study provides important clinical proof of concept supporting further development of CID-103 in autoimmune disorders, solid organ transplant rejection, and other CD38 mediated diseases with large unmet medical need."
Trade with 70% Backtested Accuracy
Analyst Views on CASI
About CASI
About the author
Dayforce Shares Surge Approximately 21%; Check Out 20 Stocks Making Moves in Premarket Trading
Dayforce Inc Acquisition Talks: Shares of Dayforce Inc rose 21.4% in pre-market trading following reports that Thoma Bravo is in discussions to acquire the company.
Notable Gainers: Other stocks experiencing significant gains include Propanc Biopharma (up 253%), Adaptimmune Therapeutics (up 70.3%), and DIH Holding US (up 43.4%).
Significant Losers: TPI Composites saw a drastic decline of 51.1%, while SRx Health Solutions and Empery Digital also faced notable drops of 25.8% and 22.2%, respectively.
Market Overview: The article highlights various stocks' movements in pre-market trading, showcasing both substantial gainers and losers, reflecting market volatility.
Premarket Stock Movements: PPCB, BTAI, TNXP, DAY, TPIC, and Other Notable Gainers and Losers
Premarket Trading Activity: Notable activity is observed in premarket trading as of 6.50 a.m. ET on Monday, indicating potential opportunities before the market opens.
Importance for Traders: Premarket trading allows active traders to identify possible breakouts, reversals, or price swings, making it crucial for analyzing momentum heading into the regular session.
Stocks Performance: Some stocks are showing significant percentage increases while others are experiencing notable declines during Monday's premarket session.
Author's Perspective: The views expressed in the article reflect the author's opinions and do not necessarily represent those of Nasdaq, Inc.
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Earnings Performance: Xenetic Biosciences reported a quarterly loss of $0.45 per share, better than the expected loss of $0.64, marking a 29.69% earnings surprise; however, revenues of $0.59 million fell short of estimates by 7.81%.
Market Outlook: The company's stock has underperformed with a 30.8% decline this year, and its future performance will depend on management's commentary and revisions to earnings estimates, currently rated as Zacks Rank #3 (Hold).
HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $4 Price Target
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
CASI Pharma Receives New $20 Mln Buyout Proposal For China Unit And Drug Rights
CASI Pharmaceuticals Proposal: CASI Pharmaceuticals Inc. announced that its Special Committee received an updated non-binding proposal from CEO Dr. Wei-Wu He to acquire the company's operations in China for $20 million, which includes assuming $20 million in debt and rights to certain products in Asia.
Evaluation of Proposal: The board has formed a Special Committee to evaluate this proposal and other strategic options, emphasizing that no decisions have been made yet and there is no guarantee that a definitive agreement will be reached.
Casi Pharmaceuticals files $200M mixed securities shelf
Casi Pharmaceuticals Filing: Casi Pharmaceuticals (CASI) has filed a $200 million mixed securities shelf registration, allowing them to raise capital through various types of securities.
Recent Performance and News: The company is currently facing challenges, including a license termination dispute regarding Evomela® and mixed financial results for Q3 2024, with an EPS of 55 cents compared to a loss of 35 cents last year.
Dayforce Shares Surge Approximately 21%; Check Out 20 Stocks Making Moves in Premarket Trading
Dayforce Inc Acquisition Talks: Shares of Dayforce Inc rose 21.4% in pre-market trading following reports that Thoma Bravo is in discussions to acquire the company.
Notable Gainers: Other stocks experiencing significant gains include Propanc Biopharma (up 253%), Adaptimmune Therapeutics (up 70.3%), and DIH Holding US (up 43.4%).
Significant Losers: TPI Composites saw a drastic decline of 51.1%, while SRx Health Solutions and Empery Digital also faced notable drops of 25.8% and 22.2%, respectively.
Market Overview: The article highlights various stocks' movements in pre-market trading, showcasing both substantial gainers and losers, reflecting market volatility.
Premarket Stock Movements: PPCB, BTAI, TNXP, DAY, TPIC, and Other Notable Gainers and Losers
Premarket Trading Activity: Notable activity is observed in premarket trading as of 6.50 a.m. ET on Monday, indicating potential opportunities before the market opens.
Importance for Traders: Premarket trading allows active traders to identify possible breakouts, reversals, or price swings, making it crucial for analyzing momentum heading into the regular session.
Stocks Performance: Some stocks are showing significant percentage increases while others are experiencing notable declines during Monday's premarket session.
Author's Perspective: The views expressed in the article reflect the author's opinions and do not necessarily represent those of Nasdaq, Inc.
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Earnings Performance: Xenetic Biosciences reported a quarterly loss of $0.45 per share, better than the expected loss of $0.64, marking a 29.69% earnings surprise; however, revenues of $0.59 million fell short of estimates by 7.81%.
Market Outlook: The company's stock has underperformed with a 30.8% decline this year, and its future performance will depend on management's commentary and revisions to earnings estimates, currently rated as Zacks Rank #3 (Hold).
HC Wainwright & Co. Reiterates Buy on CASI Pharmaceuticals, Maintains $4 Price Target
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
CASI Pharma Receives New $20 Mln Buyout Proposal For China Unit And Drug Rights
CASI Pharmaceuticals Proposal: CASI Pharmaceuticals Inc. announced that its Special Committee received an updated non-binding proposal from CEO Dr. Wei-Wu He to acquire the company's operations in China for $20 million, which includes assuming $20 million in debt and rights to certain products in Asia.
Evaluation of Proposal: The board has formed a Special Committee to evaluate this proposal and other strategic options, emphasizing that no decisions have been made yet and there is no guarantee that a definitive agreement will be reached.
Casi Pharmaceuticals files $200M mixed securities shelf
Casi Pharmaceuticals Filing: Casi Pharmaceuticals (CASI) has filed a $200 million mixed securities shelf registration, allowing them to raise capital through various types of securities.
Recent Performance and News: The company is currently facing challenges, including a license termination dispute regarding Evomela® and mixed financial results for Q3 2024, with an EPS of 55 cents compared to a loss of 35 cents last year.
